Stock Ratings / Health Care / MDXG / earnings

TCMD (78) SGHT (38) ANGO (50) RCEL (44) ⌘ Pro Terminal →

MiMedx Group Inc (MDXG) Next Earnings Date & Expected ±10.6% Move

$3.97 +0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

MiMedx Group Inc (MDXG) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (83% profit margin, 47% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $579.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDXG)Realized 20D OHLCV Swing Band: ±10.6%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10.6% Swing Band

±$0.42 Expected Swing

MODEL EARNINGS SETUP GAUGE

MDXG Quantitative Pre-Earnings Setup: 77/100

Trailing EPS: $0.33 • YoY Revenue Growth: 20%

Model Bullish Setup (77/100)Model Risk Weight (23/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$418.6M	$48.6M	$74.0M	82.6%
FY 2024	2024-12-31	$348.9M	$42.4M	$66.2M	82.8%
FY 2023	2023-12-31	$321.5M	$58.2M	$26.8M	82.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating MDXG & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on MDXG
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MDXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.15%▼ SUPPORT BREAKDOWN

2026-10-30O $3.98H $3.99L $3.79C $3.97VOL 2.12M

RES: $5.29SUP: $4.20SMA50: $4.49SMA200: $4.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDXG Butterfly Map → + Track MDXG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.3%/yr Implied 5Y Growth

vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MDXG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDXG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MDXG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDXG)

Health Care Rank #30 of 1016 ⚔️ TCMD vs MDXG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDXG vs. TCMD, SGHT, ANGO, RCEL)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MiMedx Group Inc (MDXG) ranks #30 by composite RQD confidence (77/100, grade B+) and #426 by equity capitalization ($579.3M). Within this direct 5-issuer industry benchmark cohort, MDXG leads on earnings valuation at 11.9x trailing P/E, while MDXG leads on capital efficiency and profitability with 47.2% ROIC and 82.6% gross margin. TCMD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with MDXG at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MDXG ACTIVE MiMedx Group Inc	B+	77/100	11.9x	82.6%	47.2%	+0.51%	$579.3M	Benchmark Subject
TCMD Tactile Systems Technology Inc.	B+	78/100	28.9x	75.9%	17.1%	+1.67%	$550.7M	/tcmd-vs-mdxg →
SGHT Sight Sciences Inc.	D-	38/100	—	86.2%	-35.0%	+3.57%	$527.2M	/sght-vs-mdxg →
ANGO AngioDynamics Inc.	D	50/100	—	54.6%	-23.4%	+1.81%	$519.4M	/ango-vs-mdxg →
RCEL Avita Medical Inc.	D	44/100	—	82.1%	-35.0%	+1.27%	$516.8M	/rcel-vs-mdxg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001376339

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MiMedx Group Inc (MDXG) reported GAAP revenue of $418.6M (+20.0% vs. FY2024 revenue of $348.9M , and +30.2% cumulative change since FY2023) , GAAP net income of $48.6M, operating cash flow of $74.0M, and free cash flow of $74.0M (+11.8% YoY). On the balance sheet, MDXG closed FY2025 with $342.7M in total assets against $16.5M in total debt (Altman Z-Score: 6.45, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$418.6M	$48.6M	$74.0M	$74.0M	$342.7M	$16.5M
FY2024 (FY)	2024-12-31	$348.9M	$42.4M	$66.2M	$66.2M	$263.9M	$17.8M
FY2023 (FY)	2023-12-31	$321.5M	$58.2M	$26.8M	$26.8M	—	—

3. MDXG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MiMedx Group Inc (NASDAQ: MDXG) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $3.97 (+0.51% 1D, market cap $579.3M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, MDXG ranks #30 in composite RQD confidence.

How does MDXG compare to TCMD and SGHT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), MDXG carries a Roarable B+ (77/100 RQD), trailing P/E of 11.9x, gross margin of 82.6%, and ROIC of 47.2%. By comparison, TCMD (Tactile Systems Technology Inc.) holds a B+ grade (78/100 RQD, P/E 28.9x, ROIC 17.1%, cap $550.7M) and SGHT (Sight Sciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $527.2M). Among the 5-stock peer group, MDXG leads on earnings multiple (11.9x) while MDXG leads on capital efficiency (47.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MDXG?

Per MDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001376339), MiMedx Group Inc generated $418.6M in revenue (+20.0% YoY), $48.6M in net income, and $74.0M in free cash flow against $342.7M in total assets and $16.5M in total debt. Key quantitative strengths: Strong cash generator (83% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MDXG trading relative to its 50-day, 200-day, and 52-week technical levels?

MDXG last traded at $3.97 (+0.51% on volume of 4,044,148 shares), positioning the stock -11.58% below its 50-day simple moving average ($4.49) and -7.03% below its 200-day simple moving average ($4.27). Across its 52-week range of $3.03 to $7.97, MDXG sits at the 19.0% percentile with a 14-day RSI of 32.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($3.55 to $4.39).